01:15 PM EDT, 06/03/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $343 from $321 based on our net present value analysis. We lift our 2025 EPS estimate to $0.69 from -$0.02, as we forecast improved profitability for the remainder of 2025. We increase our 2026 EPS estimate to $3.95 from $2.77. With its improving growth and profitability outlook and its portfolio in the U.S. composed of orphan drugs, we think Alnylam is better placed compared to larger peers exposed to revenue risks stemming from the Inflation Reduction Act over the next years. During the Q1 call, management also emphasized that it does not see a material impact on its performance from the tariffs that are in place and seemed confident it can absorb resulting cost increases. While the tariff environment remains dynamic, with its intellectual property in the U.S. and the majority of its products manufactured domestically, we think the company is better placed versus certain larger biotech peers to navigate ongoing uncertainties in the operating environment.